HR and breast carcinoma: Monotherapy with immune checkpoint inhibitors remains uncommon in HR+/HER2- metastatic breast cancer, but combination therapy involving CDK4/6 inhibitors and immunotherapy is being actively investigated for patients progressing on CDK4/6 inhibitors.